Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27026941 | 0.97 | APP (0.48) | APPLMNAALDH1A1TP53PTGS1 | |
| SCHEMBL2198185 | 0.94 | APP (0.50) | APPLMNAALDH1A1TP53PTGS1 | |
| SCHEMBL777321 | 0.84 | ALDH1A1 (0.52) | LMNAALDH1A1TP53NLRP3LOX | |
| SCHEMBL35183 | 0.84 | APP (0.65) | APPLMNAALDH1A1PTGS1PDE4A | |
| SCHEMBL13321333 | 0.83 | APP (0.41) | APPLMNAALDH1A1TP53PTGS1 | |
| SCHEMBL11695951 | 0.81 | LMNA (0.45) | APPLMNAALDH1A1TP53PTGS1 | |
| Hydrochloric Acid SCHEMBL8210048 | 0.81 | APP (0.61) | APPLMNAPTGS1PDE4ASLC6A6 | |
| SCHEMBL1270542 | 0.81 | APP (0.61) | APPLMNAPTGS1PDE4ASLC6A6 | |
| SCHEMBL917843 | 0.81 | APP (0.61) | APPLMNAPTGS1PDE4ASLC6A6 | |
| SCHEMBL922126 | 0.81 | APP (0.61) | APPLMNAPTGS1PDE4ASLC6A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116646606-A | Electrolyte adopting sulfonate-based deep eutectic solvent, preparation method and lithium ion battery | 常州千沐新能源有限公司 | 2023-08-25 | — | — | CN | claimed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-20240018376-A1 | AQUEOUS ADDITIVE SOLUTION FOR INK COMPOSITION, AQUEOUS COLORANT SOLUTION FOR INK COMPOSITION, INK COMPOSITION, INK COMPOSITION FOR INK JET RECORDING, AND INK JET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2024-01-18 | — | — | US | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| EP-3790871-A1 | FURIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019215341-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | WO | disclosed |
| EP-2411383-B1 | DERIVATIVES OF 3-ALKOXY-4,5-DIARYLTHIOPHENE-2-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-10-22 | — | — | EP | disclosed |
| US-8486971-B2 | Derivatives of 3-alkoxy-4,5-diarylthiophene-2-carboxamide, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2013-07-16 | — | — | US | disclosed |
| US-20120115906-A1 | DERIVATIVES OF 3-ALKOXY-4,5-DIARYLTHIOPHENE-2-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-10 | — | — | US | disclosed |
| EP-2411383-A1 | DERIVATIVES OF 3-ALKOXY-4,5-DIARYLTHIOPHENE-2-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109150-A1 | DERIVATIVES OF 3-ALKOXY-4,5-DIARYLTHIOPHENE-2-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | APP 53/4885LMNA 264/4885ALDH1A1 3733/4885 |
| US-20120115906-A1 | DERIVATIVES OF 3-ALKOXY-4,5-DIARYLTHIOPHENE-2-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | HRH4, HCRTR1, NR3C1 | APP 3264/4885LMNA 4169/4885ALDH1A1 1238/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | APP 53/4885LMNA 264/4885ALDH1A1 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.